The alternative NF-κB activation pathway and cancer: Friend or foe?;Voie alternative d'activation de NF-κB et cancer: Amis ou ennemis?

Medecine/Sciences

Volumn 24, Issue 12, 2008, Pages 1083-1088

  Baud, Véronique ^a,b   Jacque, Emilie ^a,b,c  

^a INSTITUT COCHIN   (France)

^b Maternité Port Royal Institut Cochin ^*  (France)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58449136060     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200824121083     Document Type: Review

References (39)

1. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994 ; 12 : 141-79.
2. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997 ; 336 : 1066-71.
3. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002 ; 3 : 221-7.
4. Karin M, Cao Y, Greten F, Li ZW. NF-κB in cancer : from innocent bystander to major culprit. Nat Rev Cancer 2002 ; 2 : 301-10.
5. Rayet B, Gélinas C. Aberrant Rel/NF-κB genes and activity in human cancer. Oncogene 1999 ; 18 : 6938-47.
6. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance : enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999 ; 5 : 412-17.
7. Gilmore TD. NF-kappa B, KBF1, dorsal, and related matters. Cell 1990 ; 62 : 841-3.
8. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination : the control of NF-κB activity. Annu Rev Immunol 2000 ; 18 : 621-63.
9. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology : pitfalls and promises for future drug development. Biochem Pharmacol 2006 ; 72 : 1161-79.
10. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004 ; 279 : 26243-50.
11. Derudder E, Dejardin E, Pritchard LL, et al. RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation : critical roles for p100. J Biol Chem 2003 ; 278 : 23278-84.
12. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002 ; 17 : 525-35.
13. Jacque E, Tchenio T, Piton G, et al. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci USA 2005 ; 102 : 14635-40.
14. Jacque E, Baud V. RelA, un nouvel acteur dans la régulation de l'activité de RelB. Med Sci (Paris) 2006 ; 22 : 113-4.
15. Gautheron J, Courtois, G. Les nouvelles fonctions de NEMO, la sous-unité régulatrice de la kinase activant NF-κB. Med Sci (Paris) 2008 ; 24 : 954-60.
16. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007 ; 12 : 115-30.
17. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007 ; 12 : 131-44.
18. Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA 2004 ; 101 : 9079-84.
19. Mineva RD, Rothstein TL, Meyers JA, et al. CD40 ligand-mediated activation of the de novo RelB NF-κB synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem 2007 ; 282 : 17475-85.
20. Dos Santos NR, Williame M, Gachet S, et al. RelB-dependent stromal cells promote T-cell leukemogenesis. PLos One 2008 ; 3 : e2555.
21. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. Rearranged NFκB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 1994 ; 9 : 1931-7.
22. Neri A, Fracchiolla NS, Migliazza A, et al. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma 1996 ; 23 : 43-8.
23. Derudder E, Laferte A, Ferreira V, et al. Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2. Biochem Biophys Res Commun 2003 ; 308 : 744-9.
24. Hacker H, Karin M. Is NF-kappaB2/p100 a direct activator of programmed cell death? Cancer Cell 2002 ; 2 : 431-3.
25. Malinge S, Monni R, Bernard O, Penard-Lacronique V. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 2006 ; 25 : 3589-97.
26. Demicco EG, Kavanagh KT, Romieu-Mourez R, et al. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 2005 ; 25 : 10136-47.
27. Romieu-Mourez R, Kim DW, Shin SM, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003 ; 23 : 5738-54.
28. Connelly L, Robinson-Benion C, Chont M, et al. A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 2007 ; 282 : 10028-35.
29. Wang X, Belguise K, Kersual N, et al. Estrogen signalling inhibits invasive phenotype by repressing RelB and its target BC12. Nat Cell Biol 2007 ; 9 : 470-8.
30. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer : an immunohistochemical study. Br J Cancer 2005 ; 93 : 1019-23.
31. Josson S, Xu Y, Fong F, et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006 ; 25 : 1554-9.
32. Xu Y, Fang F, St Clair DK, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveols a primary mechanism for rodiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007 ; 6 : 2048-56.
33. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999 ; 284 : 316-20.
34. Liu B, Park E, Zhu F, et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci USA 2006 ; 103 : 17202-7.
35. Park E, Zhu F, Liu B, et al. Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. Cancer Res 2007 ; 67 : 9158-68.
36. Zhu F, Xia X, Liu B, et al. IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylotion, preventing its silencing. Mol Cell 2007 ; 27 : 214-27.
37. Lobry C, Weil R. Mécanismes régulateurs de la voie NF-κB dans les lymphocytes T. Med Sci (Paris) 2007 ; 23 : 857-61.
38. Lobry C, Weil R. Nouveaux mécanismes régulateurs de Bcl10 : Une avancée dans la compréhension de la survenue des lymphomes du MALT ? Med Sci (Paris) 2007 ; 23 : 353-5.
39. Romagnoli M, Séveno C, Bataille R, Barillé-Nion S. Survivine en cancérologie : aspects moléculaires et applications thérapeutiques. Med Sci (Paris) 2008 ; 24 : 821-7.